FWY003
/ Novartis
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
March 03, 2026
A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
(clinicaltrials.gov)
- P2 | N=272 | Not yet recruiting | Sponsor: Novartis Pharmaceuticals
New P2 trial • Age-related Macular Degeneration • Dry Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders
March 10, 2026
A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
(clinicaltrials.gov)
- P2 | N=272 | Recruiting | Sponsor: Novartis Pharmaceuticals | Not yet recruiting ➔ Recruiting
Enrollment open • Age-related Macular Degeneration • Dry Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders
1 to 2
Of
2
Go to page
1